Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Investor Newsletters
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Documentation

  • Home >
  • Investors & media >
  • Documentation
08 April 2020
Financial statements and reports, Regulated information

2019 Universal Registration Document Open in new window

20 December 2019
Financial statements and reports, Regulated information

2018 Universal Registration Document Open in new window

24 July 2019
Financial statements and reports

2019 Half-Year Financial Report Open in new window

29 April 2019
Financial statements and reports

2018 Annual Financial Report Open in new window

25 July 2018
Financial statements and reports

2018 Half-Year Financial Report Open in new window

27 April 2018
Financial statements and reports

2017 Registration Document Open in new window

28 July 2017
Financial statements and reports

2017 Half-Year Financial Report Open in new window

28 April 2017
Financial statements and reports

2016 Registration Document Open in new window

  • View previous 9 articles
  • 1
  • 2
  • 3
© 2025 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page